The role of next-generation sequencing in castration-resistant prostate cancer treatment

Cancer Journal (United States)

Volumn 22, Issue 5, 2016, Pages 357-361

  Hovelson, Daniel H ^a   Tomlins, Scott A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cell free DNA; Circulating tumor cells; Exome sequencing; Molecular landscape; PARP inhibitor; Small cell carcinoma; Transcriptome sequencing

Indexed keywords

ANTIANDROGEN THERAPY; CANCER PROGNOSIS; CANCER SCREENING; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; DISEASE COURSE; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; GENOMICS; HUMAN; MALE; NEUROENDOCRINE TUMOR; NEXT GENERATION SEQUENCING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TRANSCRIPTOMICS; CLINICAL TRIAL (TOPIC); GENETICS; HIGH THROUGHPUT SEQUENCING; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84989812396     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000217     Document Type: Review

References (55)

1. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161: 1215-1228
2. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 2015; 163: 1011-1025
3. GundemG, Van Loo P, Kremeyer B, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015; 520: 353-357
4. Beltran H, Prandi D, Mosquera JM, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016; 22: 298-305
5. Kumar A, Coleman I, Morrissey C, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016; 22: 369-378
6. Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012; 487: 239-243
7. Prensner JR, Zhao S, Erho N, et al. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol. 2014; 15: 1469-1480
8. Rajan P, Stockley J, Sudbery IM, et al. Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and posttreatment prostatic biopsies from patients with advanced prostate cancer. BMC Cancer. 2014; 14: 977
9. Ylipaa A, Kivinummi K, Kohvakka A, et al. Transcriptome sequencing reveals PCAT5 as a novel ERG-regulated long noncoding RNA in prostate cancer. Cancer Res. 2015; 75: 4026-4031
10. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371: 1028-1038
11. Beltran H, Yelensky R, Frampton GM, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol. 2013; 63: 920-926
12. Hovelson DH, McDaniel AS, Cani AK, et al. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia. 2015; 17: 385-399
13. Cheng HH, Klemfuss N, Montgomery B, et al. A pilot study of clinical targeted next generation sequencing for prostate cancer: consequences for treatment and genetic counseling. Prostate. 2016
14. Cieslik M, Chugh R, Wu YM, et al. The use of exome capture RNA-Seq for highly degraded RNA with application to clinical cancer sequencing. Genome Res. 2015; 25: 1372-1381
15. Van Allen EM, Wagle N, Stojanov P, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014; 20(6): 682-688
16. Beltran H, Rubin MA. New strategies in prostate cancer: Translating genomics into the clinic. Clin Cancer Res. 2013; 19: 517-523
17. Romanel A, Gasi Tandefelt D, Conteduca V, et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med. 2015; 7: 312re310
18. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310: 644-648
19. Tomlins SA, Rhodes DR, Yu J, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell. 2008; 13: 519-528
20. AzadAA, Volik SV, WyattAW, et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castrationresistant prostate cancer. Clin Cancer Res. 2015; 21: 2315-2324
21. Carreira S, Romanel A, Goodall J, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med. 2014; 6: 254ra125
22. Wyatt AW, Azad AA, Volik SV, et al. Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer [published online ahead of print May 5, 2016]. In: JAMA Oncol. 2016
23. Lallous N, Volik SV, Awrey S, et al. Functional analysis of androgen receptor mutations that confer anti-Androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol. 2016; 17: 10
24. Ulz P, Belic J, Graf R, et al. Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. Nat Commun. 2016; 7: 12008
25. Lohr JG, Adalsteinsson VA, Cibulskis K, et al. Whole-exome sequencing of circulating tumor cells provides a windowinto metastatic prostate cancer. Nat Biotechnol. 2014; 32: 479-484
26. Miyamoto DT, Zheng Y, Wittner BS, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015; 349: 1351-1356
27. Haffner MC, Mosbruger T, Esopi DM, et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 2013; 123: 4918-4922
28. Wise AM, Stamey TA, McNeal JE, et al. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology. 2002; 60: 264-269
29. Boutros PC, Fraser M, Harding NJ, et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 2015; 47: 736-745
30. Cooper CS, Eeles R, Wedge DC, et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet. 2015; 47: 367-372
31. LiuW, Laitinen S, Khan S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009; 15: 559-565
32. HongMK, Macintyre G, Wedge DC, et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun. 2015; 6: 6605
33. Ross AE, D'Amico AV, Freedland SJ. Which, when and why?. Rational use of tissue-based molecular testing in localized prostate cancer. Prostate Cancer Prostatic Dis. 2016; 19: 1-6
34. Thompson D, Easton DF. Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002; 94: 1358-1365
35. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004; 22(4): 735-742
36. TischkowitzM, Eeles R.Mutations in BRCA1 and BRCA2 and predisposition to prostate cancer. Lancet. 2003; 362: 80; author reply 80
37. Ostrander EA, Udler MS. The role of the BRCA2 gene in susceptibility to prostate cancer revisited. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1843-1848
38. Attard G, Parker C, Eeles RA, et al. Prostate cancer. Lancet. 2016; 387 (10013): 70-82
39. Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl JMed. 2012; 366: 141-149
40. Beltran H, Rickman DS, Park K, et al.Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011; 1: 487-495
41. Epstein JI, AminMB, Beltran H, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014; 38: 756-767
42. Nadal R, Schweizer M, Kryvenko ON, et al. Small cell carcinoma of the prostate. Nat Rev Urol. 2014; 11: 213-219
43. Kadakia KC, Tomlins SA, Sanghvi SK, et al. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment. J Hematol Oncol. 2015; 8: 109
44. Grasso CS, Cani AK, Hovelson DH, et al. Integrative molecular profiling of routine clinical prostate cancer specimens. Ann Oncol. 2015; 26(6): 1110-1118
45. Aggarwal R, Zhang T, Small EJ, et al. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Cancer Netw. 2014; 12: 719-726
46. Aparicio AM, Harzstark A, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013
47. Khemlina G, Ikeda S, Kurzrock R. Molecular landscape of prostate cancer: implications for current clinical trials. Cancer Treat Rev. 2015; 41: 761-766
48. Lord CJ, Tutt AN, Ashworth A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med. 2015; 66: 455-470
49. Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl JMed. 2015; 373: 1697-1708
50. Spratt DE, Zumsteg ZS, Feng FY, et al. Translational and clinical implications of the genetic landscape of prostate cancer. In: Nat Rev Clin Oncol. 2016
51. Prensner JR, RubinMA, Wei JT, et al. Beyond PSA: The next generation of prostate cancer biomarkers. Sci Transl Med. 2012; 4: 127rv123
52. Prensner JR, Iyer MK, Sahu A, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet. 2013; 45(11): 1392-1398
53. Sprenger CC, Plymate R. The link between androgen receptor splice variants and castration-resistant prostate cancer. Horm Cancer. 2014; 5: 207-217
54. Valdes-Mora F, Clark SJ. Prostate cancer epigenetic biomarkers: nextgeneration technologies. Oncogene. 2015; 34: 1609-1618
55. Xu K, Wu ZJ, Groner AC, et al. EZH2 oncogenic activity in castrationresistant prostate cancer cells is polycomb-independent. Science. 2012; 338: 1465-1469.